HOME >> MEDICINE >> NEWS
Heart rhythm society issues draft recommendations on performance policies for pacemakers and ICDs

WASHINGTON--The Heart Rhythm Society today released the first comprehensive recommendations for the surveillance, analysis and performance reporting of pacemakers and implantable cardioverter defibrillators (ICDs). The draft guidelines offer detailed recommendations to physicians, the Food and Drug Administration (FDA), and Congress about performance issues and advisories for implanted cardiac devices.

The recommendations also provide heart patients with clearer, timelier and more consistent information about the recall and advisory process.

"As the international leader in science, education and advocacy for cardiac arrhythmia professionals and patients, we believe these suggested changes will ensure that patients continue to have access to these lifesaving treatments," said Anne B. Curtis, M.D., President of the Heart Rhythm Society. "We believe these draft guidelines are an important step towards strengthening patient and physician knowledge, confidence and trust."

The draft guidelines call for: 1.) greater transparency in the post-market surveillance, analysis, and reporting of information 2.) the establishment of new systems to identify malfunctioning devices more quickly and 3) standard notification and communication to physicians and patients from the manufacturer when a device malfunction is identified. Manufacturers, the FDA, and physicians are encouraged to work together to prevent adverse events due to device malfunctions.

Select highlights from the recommendations include the following:

Physicians:

  • Should inform patients not only about the benefits and risks of devices, but also about the overall expected performance of devices, including potential malfunction rates.
  • Should return all malfunctioning devices after explant to the manufacturer for analysis whether the replacement is routine or because of a malfunction. This will lead to more timely identification of potential malfunctions an
    '"/>


Contact: Rachael Lille Moore
rmoore@HRSonline.org
202-464-3476
GYMR
26-Apr-2006


Page: 1 2 3

Related medicine news :

1. Drug-eluting stent controversy explored in the American Heart Hospital Journal
2. Heart-failure patients benefit from pharmacist care
3. Study offers clues to Broken Heart Syndrome
4. Heart Failure 2007
5. Heart failure medication does not improve survival, compared to more widely used medication
6. UCLA neurologist honored with American Heart Associations Stroke Council Award
7. Heart failure: Mayo Clinic reveals abnormality in filling of the heart is frequent culprit
8. Heart catheters do not benefit patients
9. Heart Rhythm Society publishes final recommendations for heart patients
10. Heartburn drug may help to slow progression of chronic heart failure
11. Heart failure drugs may be beneficial for patients with hardening of the arteries

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/24/2017)... ... 24, 2017 , ... In “Sky and I”, a young boy was walking home and feeling down about himself. ... him otherwise. The new friend says he can do whatever he wants to do if ... enough just the way he is. God created him with special talents and gifts. We ...
(Date:9/24/2017)... (PRWEB) , ... September 24, 2017 , ... “The Gospel Truth Of The Bible: The ... “The Gospel Truth Of The Bible: The Other Sheep” is the creation of published author, ... born in the West Indies. He has been a member of the Seventh-day Adventist ...
(Date:9/23/2017)... ... September 23, 2017 , ... Silicon Valley Hair Institute, the leading ... new blog post focused on the ARTAS® hair transplant system and the younger demographic. ... the latest, most technologically sophisticated methods of hair restoration. , “It can be emotionally ...
(Date:9/22/2017)... ... ... MEDIA OPPORTUNITY: , Save Our Hospital - Albert Lea will host media ... against Mayo Clinic. Specifically, media can talk to steering committee members and patients regarding ... the Albert Lea hospital. , The rally aims to protect the most vulnerable and ...
(Date:9/22/2017)... PA (PRWEB) , ... September 22, 2017 , ... ... soon as possible, and they often saves lives. However, if one isn’t accessible ... to widen the availability of defibrillation, I came up with this idea," said ...
Breaking Medicine News(10 mins):
(Date:9/6/2017)... -- NeuroRx, a clinical stage biopharma company developing the first ... been granted Fast Track status by the US Food and ... followed by NRX-101 (D-cycloserine + lurasidone). The company will shortly ... therapy targeting patients who are admitted to Emergency Departments with ... ...
(Date:9/5/2017)... another milestone in their continued growth and success of the company.  Xyntek has ... engagements regionally.  ... at 318 West Adams Street, Suite 1528, Chicago, IL ... Xyntek's recently opened Midwest office will support the ... In addition to Xyntek,s headquarters ...
(Date:9/5/2017)... 2017 Oramed Pharmaceuticals Inc. (NASDAQ: ... pharmaceutical company focused on the development of oral drug ... its meeting with the U.S. Food and Drug Administration ... At the meeting, ... for submission of ORMD-0801, would be a Biologics License ...
Breaking Medicine Technology:
Cached News: